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Abstract  
A novel POLARIS gene-based analysis approach was employed to compute gene-based polygenic risk 
score (PRS) for all individuals in the latest HRC imputed GERAD (N cases=3,332 and N controls=9,832) 
data using the International Genomics of Alzheimer’s Project summary statistics (N cases=13,676 and N 
controls=27,322, excluding GERAD subjects) to identify the SNPs and weight their risk alleles for the PRS 
score. SNPs were assigned to known, protein coding genes using GENCODE (v19). SNPs are assigned 
using both 1) no window around the gene and 2) a window of 35kb upstream and 10kb downstream to 
include transcriptional regulatory elements. The overall association of a gene is determined using a 
logistic regression model, adjusting for population covariates.  
Three novel gene-wide significant genes were determined from the POLARIS gene-based analysis using a 
gene window; PPARGC1A, RORA and ZNF423. The ZNF423 gene resides in an Alzheimer’s disease (AD)-
specific protein network which also includes other AD-related genes. The PPARGC1A gene has been 
linked to energy metabolism and the generation of amyloid beta plaques and the RORA has strong links 
with genes which are differentially expressed in the hippocampus. We also demonstrate no enrichment 
for genes in either loss of function intolerant or conserved noncoding sequence regions. 
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Introduction  
Late Onset Alzheimer’s disease (LOAD) is a devastating neurodegenerative condition with a significant 
genetic heritability (Gatz et al. [2006]). The apolipoprotein E (APOE) gene is the strongest genetic risk 
factor for LOAD (Strittmatter et al. [1993]). Subsequently, more genes were found to be associated with 
AD development. The Genetic and Environmental Risk in Alzheimer’s Disease Consortium (GERAD) 
published a Genome-Wide Association Study (GWAS) that identified novel variants in CLU and PICALM 
which were associated with AD (Harold et al. [2009]). Concurrently, the European Alzheimer’s Disease 
Initiative (EADI) identified the CR1 and CLU loci to associate with AD (Lambert et al. [2013]). Subsequent 
publications by GERAD, the Alzheimer’s Disease Genetic Consortium (ADGC) and Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) Consortium identified a further 5 novel loci 
(Hollingworth et al. [2011], Naj et al. [2011], Seshadri et al. [2010]). The International Genomics of 
Alzheimer’s Project (IGAP) (Lambert et al. [2013]) consortium is an amalgamation of these four different 
genetic groups (GERAD, EADI, ADGC and CHARGE). Meta-analysis of the 4 GWAS datasets determined 11 
novel variants associated with AD were determined. A gene-based analysis has been undertaken in the 
IGAP AD data using Brown’s method (Brown [1975]). This approach determined two additional novel 
genes; TP53INP1 and IGHV1-67 (Escott-Price et al. [2014]). Additionally, low frequency risk variants have 
been identified through next generation sequencing (TREM2) (Guerreiro et al. [2013]) and an whole-
exome association study (PLCG2, TREM2 and ABI3 (Sims et al. [2017])).  
Set-based analysis is an alternative to Genome-Wide Association Study (GWAS) analyses, which 
considers the association of an individual Single Nucleotide Polymorphism (SNP) with disease. Set-based 
analyses provide more power due to the aggregate effect of multiple SNPs being larger than that of 
individual SNPs. For example, determining the association of genes rather than SNPs, is beneficial since 
genes are more robust across different populations (Li et al. [2011]). Set-based analyses are being widely 
used in the field and as expected, are able to identify novel genes or pathways associated with disease. 
Pathways clustering in eight areas of biology have been found to be associated with AD using the 
ALIGATOR (Holmans et al. [2009]) algorithm (Jones et al. [2010]) (Jones et al. [2015]). Additionally, 134 
gene-sets have been identified as being associated with Schizophrenia (SZ) that are related to nervous 
system function and development, where gene-sets are defined from single gene functional studies 
(Pocklington et al. [2015]). Other gene and gene-set analyses were considered in a SZ study investigating 
exomic variation which determined an enrichment in genes whose messenger ribonucleic acid (mRNA) 
binds to fragile X mental retardation protein (FMRP) and Loss of Function (LoF) intolerant genes 
(Leonenko et al. [2017]).  
The aim of the current study is to identify novel genes associated with AD using the largest up-to-date 
reference SNP panel, the most accurate imputation software and the latest published gene-based 
analysis approach. In this study, we used the GERAD data (Harold et al. [2009]) which have recently been 
imputed using the latest Haplotype Reference Consortium data (HRC). Polygenic Linkage disequilibrium- 
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Adjusted Risk Score (POLARIS) (Baker et al. [2018]) is a powerful gene-based method which produces a 
risk score per person per gene, adjusts for Linkage Disequilibrium (LD) between SNPs and informs the 
analysis with summary statistics from an external data set. POLARIS, unlike standard Polygenic Risk 
Score (PRS) does not require data to be pruned for LD prior to analysis, so is able to incorporate 
information from a larger number of SNPs. We employed the POLARIS approach (Baker et al. [2018]) 
and using the individual genotypes in the GERAD imputed data, produced the risk score for each 
individual for every gene considered. The IGAP (Lambert et al. [2013]) SNP summary statistic data, 
where the individuals from GERAD study were excluded, were used to generate the gene-based PRS. 
Furthermore, previous studies (e.g. Pardinas et al. [2018]) have suggested that genes associated with SZ 
are evolutionary constrained, likely due to functional importance during the neurodevelopmental 
stages. Since AD is a post-reproductive disorder, we hypothesised and tested whether genes associated 
with AD reside in conserved noncoding sequences or whether there is an enrichment of genes which are 
LoF intolerant. 
Methods  
The Haplotype Reference Consortium (HRC), version r1.1 2016, was used to impute GERAD genotype 
data on the Michigan Imputation Server (Das et al. [2016]), which to date, allows most accurate 
imputation of genetic variants. Imputed genotype probabilities (also known as dosages) were converted 
to the most probable genotype with a probability threshold of 0.9 or greater. SNPs were removed if: 
their imputation INFO-score<0.4, minor allele frequency (MAF)<0.01, missingness of genotypes≥0.05 or 
HWE<10-6. A total of 6,119,694 variants were retained. To correct for population structure and 
genotyping differences, all analyses were adjusted for gender and the top 15 principal components. 
POLARIS was applied to this GERAD (3,332 cases, 9,832 controls) imputed data, using the IGAP (Lambert 
et al. [2013]) data (17,008 cases, 37,154 controls) excluding GERAD subjects (IGAPnoGERAD) as an 
external dataset to improve power. There were 3,169,839 SNPs in common between imputed GERAD 
and IGAP summary statistics data. The GERAD imputed data contain individual genotypes for every SNP, 
enabling the production of a risk score per person, and the IGAPnoGERAD data contains effect sizes for 
every SNP, which are used to weight the risk score. A gene-based risk score was produced for every 
individual in the GERAD data.  
POLARIS adjusts for LD between SNPs and therefore, the SNPs were not pruned for LD and the entire 
data were used in this analysis. POLARIS adjusts for LD by using spectral decomposition of the 
correlation matrix between SNPs. Such a matrix was derived for each gene using the individual 
genotypes from the GERAD imputed data. To ensure that SNP alleles were coded in the same direction 
across both independent datasets; IGAPnoGERAD and imputed GERAD if alleles in IGAPnoGERAD were 
coded in the opposite direction to those in GERAD, the summary effect size for the SNP was inverted. 
SNPs with alleles AT, TA, CG or GC were excluded.  
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MAGMA (de Leeuw et al. [2015]) software offers an alternative approach to gene-based analyses. It can 
either be applied to summary statistics, or to the individual genotypes. We run both options of MAGMA 
software in our GERAD HRC imputed data. These analyses however cannot use additional 
(IGAPnoGERAD) information, but include all SNPs (N=6,119,694), as merging with the IGAPnoGERAD 
summary statistic data is not required.  
SNPs were assigned to genes using GENCODE (v19) gene models (Harrow et al. [2012]). Only genes with 
known gene status and those marked as protein coding were used. Two different gene windows were 
considered, the first used no window around the gene, only SNPs within the start and end position of 
the gene were included, and the second considered SNPs which were within 35kb upstream and 10kb 
downstream of the gene. These windows were used since it is likely to contain transcriptional regulatory 
elements (Network and Consortium Pathway Analysis Subgroup of Psychiatric Genomics [2015]). SNPs 
which belong to multiple genes were assigned to all those genes. In the HRC imputed GERAD data, 
1,122,570 SNPs were assigned to 17,072 distinct genes when no gene window was used and 2,296,690 
SNPs were assigned to 18,087 genes when the gene window was used.  
A POLARIS score was produced for each of these genes, and the overall association of the gene with AD 
is determined using a logistic regression model, adjusting for population covariates.  
It was then assessed whether genes determined from the gene-based analysis were enriched in 
conserved regions; both for genes which are evolutionary constrained LoF intolerant and those which 
reside in conserved noncoding sequences. Genes which are evolutionary constrained were determined 
using the Exome Aggregation Consortium (ExAC) which contains high quality exome sequence data for 
60,706 subjects (Lek et al. [2016]). This database contains a list of genes, so the number of genes from 
our analysis which reside in this list were determined. The conserved noncoding regions were defined 
from Babarinde et al. [2016], this data contains genomic locations for the conserved noncoding regions. 
Genes from our gene-based analysis which overlap these regions were determined. These regions are 
less likely to harbour variants of a strong effect or are less prone to variation (Babarinde et al. [2016]). 
The number of genes from the gene-based analysis with a p-value below either a nominal (0.05) or 
gene-wide threshold (2.5 × 10-6) and were in conserved regions were determined. The 2x2 contingency 
tables (not presented) have columns containing the number of genes with p-values above and below the 
p-value threshold and the rows show the number of genes in/out of conserved regions. The strength of 
association between genes residing in conserved regions and gene p-value was assessed using a chi-
squared test (or Fisher’s exact, when the cell counts in the 2x2 table were small). Since the same SNPs 
may be assigned to multiple genes, it is not possible to assume independence between genes. 
Therefore, prior to the analysis, genes within 250kb of one another were removed, retaining the most 
significantly associated gene. However, including all genes regardless of LD (not presented) does not 
change the result. 
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Results  
For the imputed GERAD data, the SNPs are assigned to 17,072 genes. Of these genes, six reach gene-
wide significance when no gene window is used. These genes are CLU, BCL3, PVRL2, TOMM40, APOE and 
CLPTM1 (see details in Table I); these have all been previously identified as being associated with AD 
(Harold et al. [2009], Lambert et al. [2013]). The majority of these associations are influenced by APOE 
since these genes are close in location to APOE. These results are shown on the Manhattan plot in Figure 
1, the gene-wide significant genes are shown in green, and those with a suggestive p-value (2.5 × 10-6 < p 
< 0.00001) are shown in blue; these are DAB1, ZNF35 and RORA. 
 
Table I: Gene-Wide Significant Genes from POLARIS Gene-based Analysis in AD Imputed Data  
  POLARIS 
Chr Gene No. of SNPs Beta SE P-value 
8 CLU 25 0.521 0.1048 6.8x10-7 
19 BCL3 5 0.927 0.1499 6.1x10-10 
19 PVRL2 95 0.637 0.0532 5.7x10-33 
19 TOMM40 20 0.454 0.0351 2.9x10-38 
19 APOE 1 2.247 0.2679 4.9x10-17 
19 CLPTM1 93 0.461 0.0965 1.8x10-6 
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Figure 1: Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD data 
 
MAGMA can be applied to both individual genotype data (termed MAGMA-PCA) or to summary statistic 
data (termed MAGMA-SUMMARY). The gene-wide significant genes from the imputed GERAD data using 
MAGMA-PCA are in Table II. This method finds three genes below the gene-wide threshold, all of which 
are in the APOE region; BCL3, PVRL2 and TOMM40 (Harold et al. [2009], Lambert et al. [2013]). 
Table II: Gene-Wide Significant Genes from MAGMA-PCA Gene-based Analysis in GERAD Imputed Data  
Chr Gene No. of SNPs MAGMA-PCA P-value 
19 BCL3 5 2.7x10-8 
19 PVRL2 92 4.9x10-35 
19 TOMM40 20 1.6x10-48 
Table III shows the gene-wide significant results for the gene-based analysis in the imputed GERAD using 
MAGMA-SUMMARY. This method uses the summary statistics of the imputed GERAD data rather than 
the individual genotypes. This analysis determines four gene-wide significant genes, all of which have 
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been previously identified or are part of the APOE region (Harold et al. [2009], Lambert et al. [2013]).  
Chr Gene No. of SNPs MAGMA-SUMM P-value 
8 CLU 25 1.5x10-6 
19 BCL3 5 9.5x10-7 
19 PVRL2 95 1.6x10-13 
19 TOMM40 20 4.0x10-26 
Table III: Gene-Wide Significant Genes from MAGMA-SUMM Gene-based Analysis in GERAD Imputed 
Data  
This analysis was repeated using a window around the gene of 35kb upstream and 10kb downstream 
since transcriptional regulatory elements are likely to be contained within this window (Network and 
Consortium Pathway Analysis Subgroup of Psychiatric Genomics [2015]). The gene-based results for the 
18,087 genes are plotted on a Manhattan plot in Figure 2. The 12 gene-wide significant genes from this 
analysis are shown in Table IV. Again, a large number of genes reside on chromosome 19 and these are 
likely influenced by the large effect of APOE. Three novel genes have been identified from this analysis: 
PPARGC1A, RORA and ZNF423. The PPARGC1A gene has been linked to energy metabolism and the 
generation of amyloid beta plaques (Katsouri et al. [2016]) and has potential relevance to the human 
aging process. The RORA gene has strong links with genes which are differentially expressed in the 
hippocampus (Acquaah-Mensah et al. [2015]). The ZNF423 gene resides in an AD-specific protein 
network which also includes other AD-related genes such as APOE, CLU, ABCA7, TREM2 etc. (Hu et al. 
[2017]). In addition, the SCARA3 gene overlaps CLU which has previously been identified as being 
associated with AD (Harold et al. [2009], Lambert et al. [2013]), and has additionally been found to be 
associated with total brain volume (Chauhan et al. [2015]). Note that the gene based analysis on IGAP 
data (Escott-Price et al. [2014]) identified some genes not found using this POLARIS approach. This could 
be because the POLARIS analysis focused on GERAD data rather than the IGAP data, and therefore does 
not have the same SNP coverage, or IGAP results could be influenced by other consortia. 
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Table IV: Gene-Wide Significant Genes from POLARIS Gene-based Analysis in GERAD Imputed Data 
Using a Gene Window (35kb Upstream and 10kb Downstream)  
 POLARIS 
Chr Gene No. of SNPs Beta SE P-value 
4 PPARGC1A 480 0.877 0.1851 2.2x10-6 
8 SCARA3 (CLU) 240 0.526 0.1064 7.8x10-7 
15 RORA 1813 0.334 0.0674 7.4x10-7 
16 ZNF423 1056 0.551 0.1163 2.1x10-6 
19 BCL3 88 0.377 0.0674 4.2x10-9 
19 CBLC 50 0.605 0.1161 1.8x10-7 
19 BCAM 71 0.556 0.0543 1.4x10-24 
19 PVRL2 160 0.546 0.0299 9.4x10-75 
19 TOMM40 108 0.500 0.0298 3.4x10-63 
19 APOE 55 0.520 0.0315 4.4x10-61 
19 APOC1 34 0.475 0.0315 1.5x10-51 
19 APOC4-APOC2 62 0.615 0.0871 1.6x10-12 
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Figure 2: Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD Data Using a Gene 
Window 35kb Upstream and 10kb Downstream  
 
The gene expression patterns in these novel genes were investigated using the BRAINEAC (Trabzuni et 
al. [2011]) database from the UK Brain Expression Consortium. For the PPARGC1A gene, the SNP 
rs67436520 has the best cis-expression quantitative trait loci (eQTL) p-value of 3.3x10-4, this is expressed 
in the hippocampus. The best cis-eQTL p-value in the RORA gene is 1.5x10-4, this is for SNP rs113223478 
which is 78.5kb upstream of the gene, and is expressed in the substantia nigra. Finally, SNP rs2270396 
has the best cis-eQTL p-value in the ZNF423 gene with a p-value of 3.0x10-5 and is expressed in the 
frontal cortex.  
The gene-based analysis results from MAGMA-PCA and MAGMA-SUMMARY using a gene window 
identified genes which are in the APOE region (results are not shown).  
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Conserved Regions  
GWAS data was interrogated for genes that are evolutionarily constrained, since such constraint 
indicates functional importance (Babarinde et al. [2016]). Genes from the gene-based analysis which are 
in the Exome Aggregation Consortium database (Lek et al. [2016]) and LoF intolerant were determined. 
Additionally, genes which overlap with conserved noncoding sequences were found (Babarinde et al. 
[2016]). It was then assessed whether there was enrichment for LoF intolerant genes or genes in 
conserved noncoding sequences using the POLARIS gene-based results in imputed data. There are 557 
independent genes which do not overlap, for these genes, there is no enrichment for genes in conserved 
regions at either the nominal or gene-wide p-value threshold (OR=0.95, p=0.9052 and OR=4.19, 
p=0.3505 respectively). Similarly, no evidence of an enrichment of genes in conserved noncoding 
regions at either the nominal or gene-wide p-value threshold (OR=2.97, p=0.5586 and OR=31.57, p=1 
respectively). Similar results were obtained for MAGMA derived p-values (results are not shown).  
In summary, there is consistently no enrichment at the gene-wide p-value threshold for genes in either 
loss of function intolerant or conserved noncoding sequence regions, potentially due to the fact that AD 
is a post-reproductive disorder.  
Discussion  
A gene-based analysis was performed using the individual genotypes in the GERAD imputed data and 
the summary statistics from IGAP data excluding the GERAD subjects was used to inform the analysis. 
When no gene window is considered, POLARIS does not identify any novel genes, only genes on 
chromosome 19 which are likely influenced by the large effect of APOE. When a gene window was 
expanded around the gene, 35kb upstream and 10kb downstream, three novel genes were found from 
the POLARIS gene-based analysis. The gene window is likely to include transcriptional regulatory 
elements in the gene (Network and Consortium Pathway Analysis Subgroup of Psychiatric Genomics 
[2015]) and thus contain SNPs influencing gene expression.  
Three novel genes were found to be associated with AD using the POLARIS method only. Gene-based 
analyses with MAGMA software identified only genome-wide significant genes in the APOE region. 
POLARIS determines a larger number of gene-wide significant genes compared to both the MAGMA 
approaches. This is consistent when the significance threshold is altered based on the number of genes 
from the analysis (0.05/no. genes). Supplementary Figures S1 and S2 show the gene p-value comparison 
between POLARIS and MAGMA-PCA and MAGMA-SUMM respectively; POLARIS generally has more 
significant p-values compared to both MAGMA approaches. This is likely due to the fact that MAGMA 
uses the GERAD data only whereas POLARIS additionally informs the analysis with the IGAPnoGERAD 
data. Thus, increasing power while maintaining the independence of the GERAD dataset. The novel 
genes are PPARGC1A, RORA and ZNF423, all of which have biological relevance to AD. 
PPARGC1A (peroxisome proliferator-activated receptor gamma co-activator 1alpha) is a transcriptional 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/374876doi: bioRxiv preprint first posted online Jul. 23, 2018; 
coactivator involved in a wide range of cellular and physiological functions. It is part of the PGC-1 family 
of transcriptional coactivators that mainly regulate mitochondrial biogenesis to in turn regulate the 
cellular energy metabolism (Luo et al. [2016]). The gene product, PGC-1, is an interacting partner of a 
wide range of nuclear receptors and transcription factors. It is associated with a wide-range of biological 
processes (Gene Ontology, http://www.ensembl.org), including response to a variety of cellular and 
external stimuli, cellular glucose homeostasis, circadian rhythm, regulation of neuron apoptosis, etc. 
Previous animal model work has shown that overexpression of hPGC-1 in APP23 mice improved spatial 
and recognition memory, along with significant reduction of Aβ deposition (Katsouri et al. [2016]). 
Furthermore, hPGC-1 overexpression also reduced the levels of proinflammatory cytokines and 
microglial activation (Nijland et al. [2014], Katsouri et al. [2016]). This suggests a direct link with recent 
genetic evidence of microglia-mediated innate immune response involvement in Alzheimer’s Disease 
(Sims et al. [2017]). In addition, an activation of PGC-1 by EKR and p38 inhibitors have been shown to 
improve spatial and learning memory in Aβ-injected rats (Ashabi et al. [2012]). PPARGC1A has also been 
implicated in the pathogenesis of other neurodegenerative disorders, namely Huntington’s and 
Parkinson’s diseases (Tsunemi et al. [2012]). 
Retinoic acid receptor-related orphan receptor alpha (RORA) is a nuclear hormone receptor and is 
involved in a variety of functions, circadian rhythm, cholesterol metabolism, inflammation, etc (Jetten et 
al. [2009]). RORA binds to genomic regions of transcription start sites of more than 3,000 genes in 
human monocytic and endothelial cell lines (Gulec et al. [2017]). RORA and PPARGC1A are close 
biological partners, with PGC-1 stimulates the expression of a number of clock genes through the 
coactivation of the ROR family of orphan nuclear receptors (Liu et al. [2007]). RORA has been shown to 
be linked to other genes previously implicated in AD (Hu et al. [2017]) and has also been implicated in a 
large number of neuropsychiatric disorders, such as post-traumatic stress disorder (Miller et al. [2013]). 
Furthermore, RORA trans-activates Il-6 and is thought to be neuro-protective in astrocytes and anti-
inflammatory in peripheral tissues (Journiac et al. [2009]). The two genes, RORA and PPARGC1A that we 
report here provide further evidence of the involvement of inflammation in the pathogenesis of 
Alzheimer’s disease. 
Finally, ZNF423 is a nuclear protein that belongs to the Kruppel-like C2H2 zinc finger proteins. ZNF423 
directs bone morphogenetic protein (BMP)-dependent signalling activity and aberrant forms impede B 
cell differentiation (Harder et al. [2013]). Furthermore, an increased gene-expression of ZNF423 has 
been associated in patients with systemic lupus erythematosus pointing to an impaired function of B 
cells in human mesenchymal stem cells (Feng et al. [2014]). ZNF423 resides in an AD-specific protein 
network (Hu et al. [2017]). ZNF423 is likely involved in DNA damage repair (Chaki et al, [2012]). 
Previously, it also has been shown that missense and LoF variants are likely pathogenic for abnormality 
of brain morphology, Joubert syndrome and Nephronophthisis with autosomal dominant or autosomal 
recessive inheritance (www.omim.org, https://www.ncbi.nlm.nih.gov/clinvar/). These disorders present 
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with a range of phenotypic characteristics, with the central nervous system being affected too (more 
specifically the cerebellar vermis). In nur12 mouse model (with introduced nonsense mutation in exon 4 
of the mouse Zfp423 gene), Alcaraz et al. [2006] observed loss of the corpus callosum, reduction of 
hippocampus, and a malformation of the cerebellum reminiscent of patients with Dandy-Walker 
syndrome. Within the cerebellum, Zfp423 was observed to be expressed in both ventricular and external 
germinal zones. Loss of Zfp423 was also observed to lead to diminished proliferation by granule cell 
precursors in the external germinal layer and abnormal differentiation and migration of ventricular 
zone-derived neurons and Bergmann glia (Alcaraz et al. [2006]). 
Genes determined from the gene-based analysis show no enrichment in conserved regions, in either 
evolutionary constrained LoF intolerant regions or in conserved noncoding sequences. This is expected 
in AD because it is a post-reproductive disorder. LoF highly penetrant rare variants in variation intolerant 
genes have been strongly linked to neurodevelopmental disorders with paediatric onset previously 
(Grozeva et al. [2015], Deciphering Developmental disorders study [2017]). Highly penetrant rare 
variants have been linked to familial AD with an early onset, but for the majority of individuals 
developing AD, this is not the case. In addition, rare copy number variants affecting haploinsufficient 
genes have been linked to SZ, but not AD (Grozeva et al. [2012], Chapman et al. [2013]). Therefore, it 
could be suggested that the mechanism of disease leading to AD, is different to mechanism leading to 
diseases with paediatric onset and are of neurodevelopmental origin.  This is pointing to divergent 
biological mechanisms across the common and rare variant signals and between disorders polygenic in 
nature. 
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Supplementary Material 
Figure S1: Gene –log10(p-value) Comparison Between POLARIS and MAGMA-PCA, with gene window 
 
Figure S2: Gene –log10(p-value) Comparison Between POLARIS and MAGMA-SUMMARY, with gene 
window 
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Figure S3: Gene –log10(p-value) Comparison Between MAGMA-PCA and MAGMA-SUMMARY, with 
gene window 
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Supplementary material. 
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